N-acetylcysteine versus N-acetylcysteine + theophylline for the prevention of contrast nephropathy

European Journal of Clinical Investigation

Volumn 39, Issue 9, 2009, Pages 793-799

  Baskurt, M ^a   Okcun, B ^a   Abaci, O ^a   Dogan, G M ^a   Kilickesmez, K ^a   Ozkan, A A ^a   Ersanli, M ^a   Gurmen, T ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Cardiac catheterization; Contrast induced nephropathy

Indexed keywords

ACETYLCYSTEINE; CREATININE; IOVERSOL; ISOTONIC SOLUTION; THEOPHYLLINE;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTRAST INDUCED NEPHROPATHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIZZINESS; DRUG EFFECT; DRUG EFFICACY; FEMALE; GASTROINTESTINAL SYMPTOM; GLOMERULUS FILTRATION RATE; HEART ARRHYTHMIA; HUMAN; HYDRATION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NAUSEA; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

ACETYLCYSTEINE; AGED; CONTRAST MEDIA; CORONARY ANGIOGRAPHY; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INCIDENCE; KIDNEY DISEASES; MALE; SODIUM CHLORIDE; THEOPHYLLINE;

EID: 68349139193     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2009.02173.x     Document Type: Article

References (47)

1. Maitino AJ, Levin DC, Parker L, Rao VM, Sunshine JH. Nationwide trends in rates of utilization of noninvasive diagnostic imaging among the medicare population between 1993 and 1999. Radiology 2003 227 : 113 7.
2. McCullough PA. Contrast-induced acute kidney injury. J Am Coll Cardiol 2008 51 : 1419 28.
3. Carbonell N, Blasco M, Sanjuán R, Pérez-Sancho E, Sanchis J, Insa L et al. Intravenous N-acetylcysteine for preventing contrast-induced nephropathy: a randomised trial. Int J Cardiol 2007 115 : 57 62.
4. Schweiger MJ, Chambers CE, Davidson CJ, Blankenship J, Bhalla NP, Block PC et al. Prevention of contrast induced nephropathy: recommendations for the high risk patient undergoing cardiovascular procedures. Catheter Cardiovasc Interv 2007 69 : 135 40.
5. Tepel M, van der Giet M, Schwarzfeld C, Laufer U, Liermann D, Zidek W. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med 2000 343 : 180 4.
6. Alonso A, Lau J, Jaber BL, Weintraub A, Sarnak MJ. Prevention of radiocontrast nephropathy with N-acetylcysteine in patients with chronic kidney disease: a meta-analysis of randomized, controlled trials. Am J Kidney Dis 2004 43 : 1 9.
7. MacNeill BD, Harding SA, Bazari H, Patton KK, Colon-Hernadez P, DeJoseph D et al. Prophylaxis of contrast-induced nephropathy in patients undergoing coronary angiography. Catheter Cardiovasc Interv 2003 60 : 458 61.
8. Webb JG, Pate GE, Humphries KH, Buller CE, Shalansky S, Al Shamari A et al. A randomized controlled trial of intravenous N-acetylcysteine for the prevention of contrast-induced nephropathy after cardiac catheterization: lack of effect. Am Heart J 2004 148 : 422 9.
9. Diaz-Sandoval LJ, Kosowsky BD, Losordo DW. Acetylcysteine to prevent angiography-related renal tissue injury (the APART trial). Am J Cardiol 2002 89 : 356 8.
10. Miner SE, Dzavik V, Nguyen-Ho P, Richardson R, Mitchell J, Atchison D et al. N-acetylcysteine reduces contrast-associated nephropathy but not clinical events during long-term follow-up. Am Heart J 2004 148 : 690 5.
11. Fung JW, Szeto CC, Chan WW, Kum LC, Chan AK, Wong JT et al. Effect of N-acetylcysteine for prevention of contrast nephropathy in patients with moderate to severe renal insufficiency: a randomized trial. Am J Kidney Dis 2004 43 : 801 8.
12. Nallamothu BK, Shojania KG, Saint S, Hofer TP, Humes HD, Moscucci M et al. Is acetylcysteine effective in preventing contrast-related nephropathy? A meta-analysis. Am J Med 2004 117 : 938 47.
13. Duong MH, MacKenzie TA, Malenka DJ. N-acetylcysteine prophylaxis significantly reduces the risk of radiocontrast-induced nephropathy: comprehensive meta-analysis. Catheter Cardiovasc Interv 2005 64 : 471 9.
14. Kelly AM, Dwamena B, Cronin P, Bernstein SJ, Carlos RC. Meta-analysis: effectiveness of drugs for preventing contrast-induced nephropathy. Ann Intern Med 2008 148 : 284 94.
15. Fishbane S. N-acetylcysteine in the prevention of contrast-induced nephropathy. Clin J Am Soc Nephrol 2008 3 : 281 7.
16. Al-Ghonaim M, Pannu N. Prevention and treatment of contrast-induced nephropathy. Tech Vasc Interv Radiol 2006 9 : 42 9.
17. Ix JH, McCulloch CE, Chertow GM. Theophylline for the prevention of radiocontrast nephropathy: a meta-analysis. Nephrol Dial Transplant 2004 19 : 2747 53.
18. Huber W, Schipek C, Ilgmann K, Page M, Hennig M, Wacker A et al. Effectiveness of theophylline prophylaxis of renal impairment after coronary angiography in patients with chronic renal insufficiency. Am J Cardiol 2003 91 : 1157 62.
19. Pucelikova T, Dangas G, Mehran R. Contrast-induced nephropathy. Catheter Cardiovasc Interv 2008 71 : 62 72.
20. Huber W, Eckel F, Hennig M, Rosenbrock H, Wacker A, Saur D et al. Prophylaxis of contrast material-induced nephropathy in patients in intensive care: acetylcysteine, theophylline, or both? A randomized study. Radiology 2006 239 : 793 804.
21. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999 130 : 461 70.
22. Upton RA. Pharmacokinetic interactions between theophylline and other medication. Clin Pharmacokinet 1991 20 : 66 80.
23. Hou SH, Bushinsky DA, Wish JB, Cohen JJ, Harrington JT. Hospital-acquired renal insufficiency: a prospective study. Am J Med 1983 74 : 243 8.
24. Wong GT, Irwin MG. Contrast-induced nephropathy. Br J Anaesth 2007 99 : 474 83.
25. McCullough PA, Wolyn R, Rocher LL, Levin RN, O'Neill WW. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med 1997 103 : 368 75.
26. Gruberg L, Mehran R, Dangas G, Mintz GS, Waksman R, Kent KM et al. Acute renal failure requiring dialysis after percutaneous coronary interventions. Catheter Cardiovasc Interv 2001 52 : 409 16.
27. McCullough PA, Adam A, Becker CR, Davidson C, Lameire N, Stacul F et al. Risk prediction of contrast-induced nephropathy. Am J Cardiol 2006 98 : 27K 36K.
28. Morcos SK. Contrast-induced nephropathy: are there differences between low osmolar and iso-osmolar iodinated contrast media? Clin Radiol 2009 64 : 468 72.
29. Zagler A, Azadpour M, Mercado C, Hennekens CH. N-acetylcysteine and contrast-induced nephropathy: a meta-analysis of 13 randomized trials. Am Heart J 2006 151 : 140 5.
30. Khanal S, Attallah N, Smith DE, Kline-Rogers E, Share D, O'Donnell MJ et al. Statin therapy reduces contrast-induced nephropathy: an analysis of contemporary percutaneous interventions. Am J Med 2005 118 : 843 9.
31. Spargias K, Alexopoulos E, Kyrzopoulos S, Iokovis P, Greenwood DC, Manginas A et al. Ascorbic acid prevents contrast-mediated nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention. Circulation 2004 110 : 2837 42.
32. Recio-Mayoral A, Chaparro M, Prado B, Cózar R, Méndez I, Banerjee D et al. The reno-protective effect of hydration with sodium bicarbonate plus N-acetylcysteine in patients undergoing emergency percutaneous coronary intervention: the RENO Study. J Am Coll Cardiol 2007 49 : 1283 8.
33. Hogan SE, L'Allier P, Chetcuti S, Grossman PM, Nallamothu BK, Duvernoy C et al. Current role of sodium bicarbonate-based preprocedural hydration for the prevention of contrast-induced acute kidney injury: a meta-analysis. Am Heart J 2008 156 : 414 21.
34. Katholi RE, Taylor GJ, McCann WP, Woods WT Jr., Womack KA, McCoy CD et al. Nephrotoxicity from contrast media: attenuation with theophylline. Radiology 1995 195 : 17 22.
35. Vanholder R, Van Landschoot N, De Smet R, Schoots A, Ringoir S. Drug protein binding in chronic renal failure: evaluation of nine drugs. Kidney Int 1988 33 : 996 1004.
36. Huber W, Ilgmann K, Page M, Hennig M, Schweigart U, Jeschke B et al. Effect of theophylline on contrast material-nephropathy in patients with chronic renal insufficiency: controlled, randomized, double-blinded study. Radiology 2002 223 : 772 9.
37. Bagshaw SM, Ghali WA. Theophylline for prevention of contrast-induced nephropathy: a systematic review and meta-analysis. Arch Intern Med 2005 165 : 1087 93.
38. Kapoor A, Kumar S, Gulati S, Gambhir S, Sethi RS, Sinha N. The role of theophylline in contrast-induced nephropathy: a case-control study. Nephrol Dial Transplant 2002 17 : 1936 41.
39. Briguori C, Manganelli F, Scarpato P, Elia PP, Golia B, Riviezzo G et al. Acetylcysteine and contrast agent-associated nephrotoxicity. J Am Coll Cardiol 2002 40 : 298 303.
40. Gonzales DA, Norsworthy KJ, Kern SJ, Banks S, Sieving PC, Star RA et al. A meta-analysis of N-acetylcysteine in contrast-induced nephrotoxicity: unsupervised clustering to resolve heterogenity. BMC Med 2007 5 : 32.
41. Birck R, Krzossok S, Markowetz F, Schnülle P, van der Woude FJ, Braun C. Acetylcysteine for prevention of contrast nephropathy: meta-analysis. Lancet 2003 362 : 598 603.
42. Shyu KG, Cheng JJ, Kuan P. Acetylcysteine protects against acute renal damage in patients with abnormal renal function undergoing a coronary procedure. J Am Coll Cardiol 2002 40 : 1383 8.
43. Kay J, Chow WH, Chan TM, Lo SK, Kwok OH, Yip A et al. Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: a randomized controlled trial. JAMA 2003 289 : 553 8.
44. Kshirsagar AV, Poole C, Mottl A, Shoham D, Franceschini N, Tudor G et al. N-acetylcysteine for the prevention of radiocontrast induced nephropathy: a meta-analysis of prospective controlled trials. J Am Soc Nephrol 2004 15 : 761 9.
45. Poletti PA, Saudan P, Platon A, Mermillod B, Sautter AM, Vermeulen B et al. I.v. N-acetylcysteine and emergency CT: use of serum creatinine and cystatin C as markers of radiocontrast nephrotoxicity. AJR Am J Roentgenol 2007 189 : 687 92.
46. Hoffmann U, Fischereder M, Krüger B, Drobnik W, Krämer BK. The value of N-acetylcysteine in the prevention of radiocontrast agent-induced nephropathy seems questionable. J Am Soc Nephrol 2004 15 : 407 10.
47. Solomon RJ, Natarajan MK, Doucet S, Sharma SK, Staniloae CS, Katholi RE et al. Cardiac Angiography in Renally Impaired Patients (CARE) study: a randomized double-blind trial of contrast-induced nephropathy in patients with chronic kidney disease. Circulation 2007 115 : 3189 96.